Physician profile
Ashley E Stemley
NPI 1942582739
$5,240.25
in general payments reported to CMS, 2019-2025
19 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $29.80 · 2023: $790 · 2024: $2,528 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,980 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,979.57 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,501.06 | 2023-2025 | |
| Amgen INC. | $646.05 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $641.51 | 2023-2024 | Vtama |
| Abbvie INC. | $640.41 | 2021-2025 | |
| Ucb, INC. | $356.89 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $337.25 | 2023-2025 | |
| Leo Pharma INC. | $303.15 | 2023-2025 | Adbry |
| Janssen Biotech, INC. | $259.90 | 2023-2024 | Tremfya |
| Organon LLC | $122.97 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $109.41 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $75.62 | 2024-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $73.07 | 2025 | Zoryve |
| Csl Behring | $34.98 | 2021 | |
| Smith+Nephew, INC. | $29.80 | 2022 | |
| Lilly USA, LLC | $29.08 | 2024 | Olumiant |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $21.66 | 2021 | |
| Sun Pharmaceutical Industries INC. | $20.86 | 2025 | |
| Verrica Pharmaceuticals INC. | $20.64 | 2024 | Ycanth |
| Lnhc, INC | $15.94 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Stemley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.